Syros to Participate in Upcoming Investor Conferences in March

Article Stock Quotes (1)

FREE Breaking News Alerts from StreetInsider.com!

StreetInsider.com Top Tickers, 8/20/2026

1. MRNA
2. KEYS
3. KLAR
4. PANW
5. MRK

6. HD
7. SPY
8. DVLT
9. NBIS
10. PGR

Get Alerts SYRS Hot Sheet

Price: $0.12 --0%

Overall Analyst Rating:
SELL (= Flat)

Join SI Premium – FREE

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Syros Pharmaceuticals (NASDAQ: SYRS), a leader in the development of medicines that control the expression of genes, today announced it will present at the following upcoming investor conferences.

Cowen and Company 39th Annual Health Care Conference in Boston on Wednesday, March 13, 2019 at 10:00 a.m. ET.
Oppenheimer 29th Annual Healthcare Conference in New York City on Wednesday March 20, 2019 at 3:20 p.m. ET.

The company will also participate in the 31st Annual ROTH Conference in Laguna Niguel, Calif., on Monday, March 18, 2019.

Live webcasts of the presentations will be available on the Investors & Media section of the Syros website at www.syros.com. An archived replay of the webcasts will be available for approximately 30 days following each presentation.

About Syros Pharmaceuticals

Syros is pioneering the understanding of the non-coding regulatory region of the genome to advance a new wave of medicines that control the expression of genes. Syros has built a proprietary platform that is designed to systematically and efficiently analyze this unexploited region of DNA to identify and drug novel targets linked to genomically defined patient populations. Because gene expression is fundamental to the function of all cells, Syrosâ gene control platform has broad potential to create medicines that achieve profound and durable benefit across a range of diseases. Syros is currently focused on cancer and monogenic diseases and is advancing a growing pipeline of gene control medicines. Syrosâ lead drug candidates are SY-1425, a selective RARÎ± agonist in a Phase 2 clinical trial for genomically defined subsets of patients with acute myeloid leukemia, and SY-1365, a selective CDK7 inhibitor in a Phase 1 clinical trial focused on patients with ovarian and breast cancers. Syros is also developing a deep preclinical and discovery pipeline, including SY-5609, an oral CDK7 inhibitor, as well as programs in immuno-oncology and sickle cell disease. Led by a team with deep experience in drug discovery, development and commercialization, Syros is located in Cambridge, Mass.